Clinuvel Pharmaceuticals Limited
Clinuvel Pharmaceuticals Limited (CLVLF) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Clinuvel Pharmaceuticals Limited (CLVLF), covering cash flow, earnings, and balance sheets.
Clinuvel Pharmaceuticals Limited (CLVLF) Income Statement & Financial Overview
Explore comprehensive income reports for Clinuvel Pharmaceuticals Limited CLVLF, broken down by year and quarter.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $55.38M | $32.26M | $48.97M | $24.48M |
| Cost of Revenue | $5.29M | $15.34M | $15.47M | $2.13M |
| Gross Profit | $50.09M | $16.92M | $33.49M | $22.35M |
| Gross Profit Ratio | $0.90 | $0.52 | $0.68 | $0.91 |
| R&D Expenses | $1.60M | $752499.00 | $678203.00 | $339101.00 |
| SG&A Expenses | $13.82M | $4.84M | $4.88M | $6.88M |
| Operating Expenses | $15.41M | $5.59M | $5.56M | $7.18M |
| Total Costs & Expenses | $23.70M | $20.92M | $21.04M | $9.31M |
| Interest Income | $3.66M | $3.66M | $2.57M | $321959.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $177754.00 | $575430.00 | $413322.00 | $10587.00 |
| EBITDA | $34.85M | $14.47M | $14.94M | $14.94M |
| EBITDA Ratio | $0.63 | $0.37 | $0.58 | $0.61 |
| Operating Income | $32.22M | $11.33M | $27.93M | $14.93M |
| Operating Income Ratio | $0.58 | $0.35 | $0.57 | $0.61 |
| Other Income/Expenses (Net) | $3.65M | $332689.00 | $16.04M | $555355.00 |
| Income Before Tax | $35.87M | $14.81M | $30.98M | $15.49M |
| Income Before Tax Ratio | $0.65 | $0.46 | $0.63 | $0.63 |
| Income Tax Expense | $11.17M | $3.87M | $11.76M | $5.88M |
| Net Income | $24.70M | $10.94M | $19.22M | $9.61M |
| Net Income Ratio | $0.45 | $0.34 | $0.39 | $0.39 |
| EPS | $0.49 | $0.22 | $0.39 | $0.19 |
| Diluted EPS | $0.49 | $0.21 | $0.37 | $0.19 |
| Weighted Avg Shares Outstanding | $50.51M | $50.13M | $49.41M | $51.82M |
| Weighted Avg Shares Outstanding (Diluted) | $50.47M | $51.59M | $51.85M | $51.87M |
Over the past four quarters, Clinuvel Pharmaceuticals Limited demonstrated steady revenue growth, increasing from $24.48M in Q3 2023 to $55.38M in Q4 2024. Operating income reached $32.22M in Q4 2024, maintaining a consistent 58% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $34.85M, reflecting operational efficiency. Net income rose to $24.70M, with EPS at $0.49. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan